Skip to main content
. 2014 Nov 1;6(6):1631–1637. doi: 10.4161/mabs.36107

Figure 4.

Figure 4.

Comparison of distribution of [125I]- vs. [111In]–anti-DLL4 in the lungs and liver over time following administration either as tracer alone or with 2 mg/kg and 20 mg/kg of unlabeled anti-DLL4. Radioactivity levels were assessed at 15 min, 4 h, 24 h, 4 d, and 7 d (Mean ± SD, n = 3 per time point per group). (A) [125I]-anti-DLL4 in lungs; (B) [111In]-anti-Dll4 in the lungs; (C) [125I]-anti-DLL4 in liver; (D) [111In]-anti-DLL4 in the liver.